The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Brentuximab vedotin and CHP for PTCL: upcoming Phase II trial
Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH discusses the upcoming Phase II trial (NCT04569032) assessing brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma (excluding systemic anaplastic large cell lymphoma (sALCL)) with less than 10% CD30 expression, following the success of the Phase III ECHELON-2 trial. The trial will have two arms, including 40 patients with CD30 less than 10% and 40 patients with undetectable CD30 who will be assessed for a total of 6 cycles. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding: MEI Pharma, Debiopharm Group, Regeneron
Membership on an entity’s Board of Directors or advisory committees: Verastem, Seattle Genetics
